Who are Lubiprostone 24's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amitiza (Lubiprostone), lubiprostone (Amitiza), Cohort 1: Lubiprostone Capsule, Fasted.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lubiprostone-24.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lubiprostone 24 — Competitive Intelligence Brief

Lubiprostone 24 (Lubiprostone 24) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ClC-2 chloride channel activator. Area: Gastroenterology.

phase 3 ClC-2 chloride channel activator ClC-2 chloride channel Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Lubiprostone 24 (Lubiprostone 24) — Sucampo Pharma Americas, LLC. Lubiprostone is a ClC-2 chloride channel activator that increases intestinal fluid secretion and promotes bowel motility to relieve constipation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lubiprostone 24 TARGET	Lubiprostone 24	Sucampo Pharma Americas, LLC	phase 3	ClC-2 chloride channel activator	ClC-2 chloride channel
Amitiza (Lubiprostone)	Amitiza (Lubiprostone)	Brooke Army Medical Center	marketed	Chloride channel activator	ClC-2 chloride channel
lubiprostone (Amitiza)	lubiprostone (Amitiza)	Henry Ford Health System	marketed	ClC-2 chloride channel activator	ClC-2 chloride channel
Cohort 1: Lubiprostone Capsule, Fasted	Cohort 1: Lubiprostone Capsule, Fasted	Sucampo Pharma Americas, LLC	phase 3	Chloride channel activator	ClC-2 chloride channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ClC-2 chloride channel activator class)

Henry Ford Health System · 1 drug in this class
Sucampo Pharma Americas, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lubiprostone 24 — Competitive Intelligence Brief. https://druglandscape.com/ci/lubiprostone-24. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab